ARTICLE
28 August 2025

The Future Of Life Sciences Facilities

BS
Ballard Spahr LLP

Contributor

Ballard Spahr LLP—an Am Law 100 law firm with more than 750 lawyers in 18 U.S. offices—serves clients across industries in litigation, transactions, and regulatory compliance. A strategic legal partner to clients, Ballard goes beyond to deliver actionable, forward-thinking counsel and advocacy powered by deep industry experience and an understanding of each client’s specific business goals. Our culture is defined by an entrepreneurial spirit, collaborative environment, and top-down focus on service, efficiency, and results.
The life science real estate market is undergoing a period of adjustment in 2025, marked by ups and downs in different segments of the life science sector.
United States Food, Drugs, Healthcare, Life Sciences

This article is part of the Life Sciences Industry 2025 Market Update. Click here to read the full newsletter.

The life science real estate market is undergoing a period of adjustment in 2025, marked by ups and downs in different segments of the life science sector. Following the frenetic pace of recent years, the market has cooled and is recalibrating toward a more sustainable growth trajectory. A key trend is the bifurcation of the market, where high-quality, Class A assets in established innovation hubs continue to command strong interest, while secondary properties face downward pressure on rents and higher vacancy rates. This "flight to quality" is driven by tenants seeking spaces that can attract and retain top talent, with a focus on amenity-rich buildings in prime locations.

Another significant development emerging in 2025 is the strong investment in biomanufacturing facilities. A notable number of pharmaceutical companies are announcing new U.S. investments, a trend driven by strategic decisions to "near-shore" operations and strengthen supply chains. This shift is creating a robust demand for manufacturing space, which has been undersupplied in many markets. This move toward domestic production, influenced by post-pandemic federal policies, is a bright spot in a life science real estate market that has witnessed a deceleration in the construction pipeline and new lab leasing. However, many commentators have observed that this contraction of new construction is expected to restore the balance between supply and demand over the next couple of years, and, with resurgence of venture capital into this arena, we should expect an uptick in new leasing in the not-too-distant future.

Looking ahead, the sector's resilience is underpinned by strong long-term fundamentals. The demand for cutting-edge lab and research space is propelled by demographic shifts, an aging global population, and a relentless drive for innovation. Technological advancements, particularly in AI-driven drug discovery and personalized medicine, are also reshaping real estate needs, with a growing emphasis on computational labs and data centers. As the life sciences industry continues to evolve, the real estate market is adapting with it, positioning itself for continued growth and innovation well beyond 2025.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More